We specialise in a wide range of modalities typically used to produce innovative anti-cancer treatments, including antibody drug conjugates (ADCs) and monoclonal antibodies (mAbs). Our dedicated staff helps get your drug product released quickly and efficiently.
Compare the mechanisms of traditional anticancer drugs with the next generation of therapeutics in this new article written by Commercial Director David Collins. David discusses the new emerging modalities designed to elicit improved targeted efficacy whilst reducing side effects for patients.
Symbiosis are the leading fast access CMO for clinical or small scale commercial manufacture and our offering is built upon the following principles:
It’s estimated there will be 28 million new cases of cancer worldwide each year by 2040. The requirement for innovative oncology therapeutics has never been greater. In this 9-page document we explore the modalities both commonly used and emerging for the development of new anti-cancer therapies.
We understand that in order to support clinical development of anti-caners, aseptic manufacturers must perform fill/finish within strict timeframes. Our experienced teams work collaboratively with you to facilitate your oncology therapeutic batches.
Get in touch to explore how we are positioned to assist you.
Antibody-drug conjugates (ADCs) are a rapidly emerging class of therapeutic agents that combine the target specificity of a monoclonal antibody (mAb) with the lethality of a cytotoxic payload. With ongoing advancements in drug engineering and fresh biologic insight into mechanisms of drug action, the ADC field is still early in its evolution but represents an exciting opportunity in the fight against cancer. In this infographic, we explore their importance as an advancing treatment and how manufacturing is revolutionizing the treatment of solid tumors.